Effects of temporary ERT interruption were described in more detail in other lysosomal storage diseases like Gaucher disease type I and mucopolysaccharidoses (MPS). Drelichman et al. [27] reported a group of Gaucher type I patients, that after 1 to 7 years of ERT, none had skeletal manifestations, organomegaly had decreased or disappeared and hematologic features had improved. However, after 15 to 36 months of ERT interruption, splenomegaly recurred or worsened in all children, hepatomegaly and hematologic features recurred or worsened, serious bone manifestations developed in 4 children, and 3 children experienced growth retardation. They concluded that skeletal manifestations did not resolve after treatment reinstatement. In MPS, ERT interruption can lead to the loss of the beneficial effects and, in some circumstances, the abrupt withdrawal of ERT significantly worsened the clinical evolution of the patient, especially if the interruptions were for more than two months [[28], [29], [30], [31]].